A Pooled Analysis of Diffusion-Weighted Imaging Lesions in Patients With Acute Intracerebral Hemorrhage.


Journal

JAMA neurology
ISSN: 2168-6157
Titre abrégé: JAMA Neurol
Pays: United States
ID NLM: 101589536

Informations de publication

Date de publication:
01 11 2020
Historique:
pubmed: 21 7 2020
medline: 22 6 2021
entrez: 21 7 2020
Statut: ppublish

Résumé

The etiology and significance of diffusion-weighted imaging (DWI) lesions in patients with acute intracerebral hemorrhage (ICH) remain unclear. To evaluate which factors are associated with DWI lesions, whether associated factors differ by ICH location, and whether DWI lesions are associated with functional outcomes. This analysis pooled individual patient data from 3 randomized clinical trials (Minimally Invasive Surgery Plus Alteplase for Intracerebral Hemorrhage Evacuation phase 3 trial, Antihypertensive Treatment of Acute Cerebral Hemorrhage trial, and Intracerebral Hemorrhage Deferoxamine phase 2 trial) and 1 multicenter prospective study (Ethnic/Racial Variations of Intracerebral Hemorrhage). Patients were enrolled from August 1, 2010, to September 30, 2018. Of the 4782 patients, 1788 who underwent magnetic resonance imaging scans of the brain were included. Data were analyzed from July 1 to December 31, 2019. The primary outcome consisted of factors associated with DWI lesions. Secondary outcomes were poor functional outcome, defined as a modified Rankin score (mRS) of 4 to 6, and mortality, both assessed at 3 months. Mixed-effects logistic regression was used to evaluate the association between exposures and outcomes. Subgroup analyses stratified by hematoma location were performed. After exclusion of 36 patients with missing data on DWI lesions, 1752 patients were included in the analysis (1019 men [58.2%]; mean [SD] age, 60.8 [13.3] years). Diffusion-weighted imaging lesions occurred in 549 patients (31.3%). In mixed-effects regression models, factors associated with DWI lesions included younger age (odds ratio [OR] per year, 0.98; 95% CI, 0.97-0.99), black race (OR, 1.64; 95% CI, 1.17-2.30), admission systolic blood pressure (OR per 10-mm Hg increase, 1.13; 95% CI, 1.08-1.18), baseline hematoma volume (OR per 10-mL increase, 1.12; 95% CI, 1.02-1.22), cerebral microbleeds (OR, 1.85; 95% CI, 1.39-2.46), and leukoaraiosis (OR, 1.59; 95% CI, 1.67-2.17). Diffusion-weighted imaging lesions were independently associated with poor mRS (OR, 1.50; 95% CI, 1.13-2.00), but not with mortality (OR, 1.11; 95% CI, 0.72-1.71). In subgroup analyses, similar factors were associated with DWI lesions in lobar and deep ICH. Diffusion-weighted imaging lesions were associated with poor mRS in deep but not lobar ICH. In a large, heterogeneous cohort of prospectively identified patients with ICH, results were consistent with the hypothesis that DWI lesions represent acute sequelae of chronic cerebral small vessel disease, particularly hypertensive vasculopathy. Diffusion-weighted imaging lesions portend a worse prognosis after ICH, mainly deep hemorrhages.

Identifiants

pubmed: 32687564
pii: 2768385
doi: 10.1001/jamaneurol.2020.2349
pmc: PMC7372494
doi:

Substances chimiques

Fibrinolytic Agents 0
Tissue Plasminogen Activator EC 3.4.21.68

Types de publication

Journal Article Meta-Analysis Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1390-1397

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS080824
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS074425
Pays : United States
Organisme : NIA NIH HHS
ID : K76 AG059992
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS069763
Pays : United States
Organisme : NINDS NIH HHS
ID : K23 NS105948
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS036695
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS062091
Pays : United States

Auteurs

Santosh B Murthy (SB)

Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute, Department of Neurology, Weill Cornell Medicine, New York, New York.

Sung-Min Cho (SM)

Division of Neurosciences Critical Care, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Ajay Gupta (A)

Department of Radiology, Weill Cornell Medicine, New York, New York.

Ashkan Shoamanesh (A)

Population Health Research Institute, Department of Neurology, McMaster University, Hamilton, Ontario, Canada.

Babak B Navi (BB)

Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute, Department of Neurology, Weill Cornell Medicine, New York, New York.

Radhika Avadhani (R)

Brain Injury Outcomes Division, The Johns Hopkins University, Baltimore, Maryland.

Joshua Gruber (J)

Brain Injury Outcomes Division, The Johns Hopkins University, Baltimore, Maryland.

Yunke Li (Y)

Brain Injury Outcomes Division, The Johns Hopkins University, Baltimore, Maryland.

Tatiana Greige (T)

Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Vasileios-Arsenios Lioutas (VA)

Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Casey Norton (C)

Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Cenai Zhang (C)

Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute, Department of Neurology, Weill Cornell Medicine, New York, New York.

Pitchaiah Mandava (P)

Stroke Outcomes Laboratory, Department of Neurology, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, Texas.

Costantino Iadecola (C)

Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute, Department of Neurology, Weill Cornell Medicine, New York, New York.

Guido J Falcone (GJ)

Division of Neurocritical Care and Emergency Neurology, Department of Neurology, Yale University School of Medicine, New Haven, Connecticut.

Kevin N Sheth (KN)

Division of Neurocritical Care and Emergency Neurology, Department of Neurology, Yale University School of Medicine, New Haven, Connecticut.

Alessandro Biffi (A)

Henry and Allison McCance Center for Brain Health, Massachusetts General Hospital, Boston.
Hemorrhagic Stroke Research Program, J. Philip Kistler Stroke Research Center, Massachusetts General Hospital, Boston.

Jonathan Rosand (J)

Henry and Allison McCance Center for Brain Health, Massachusetts General Hospital, Boston.
Hemorrhagic Stroke Research Program, J. Philip Kistler Stroke Research Center, Massachusetts General Hospital, Boston.

Adnan I Qureshi (AI)

Department of Neurology, University of Missouri, Columbia.

Joshua N Goldstein (JN)

Department of Emergency Medicine, Massachusetts General Hospital, Boston.

Chelsea Kidwell (C)

Department of Radiology, University of Arizona, Tucson.

Issam Awad (I)

Department of Neurological Surgery, University of Chicago School of Medicine, Chicago, Illinois.

Magdy Selim (M)

Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Daniel F Hanley (DF)

Brain Injury Outcomes Division, The Johns Hopkins University, Baltimore, Maryland.

Daniel Woo (D)

Department of Neurology, University of Cincinnati, Cincinnati, Ohio.

Hooman Kamel (H)

Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute, Department of Neurology, Weill Cornell Medicine, New York, New York.

Wendy C Ziai (WC)

Division of Neurosciences Critical Care, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH